177 related articles for article (PubMed ID: 34228761)
1. Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques.
Van Rompay KKA; Olstad KJ; Sammak RL; Dutra J; Watanabe JK; Usachenko JL; Immareddy R; Verma A; Shaan Lakshmanappa Y; Schmidt BA; Roh JW; Elizaldi SR; Allen AM; Muecksch F; Lorenzi JCC; Lockwood S; Pollard RE; Yee JL; Nham PB; Ardeshir A; Deere JD; Patterson J; Dang Q; Hatziioannou T; Bieniasz PD; Iyer SS; Hartigan-O'Connor DJ; Nussenzweig MC; Reader JR
PLoS Pathog; 2021 Jul; 17(7):e1009688. PubMed ID: 34228761
[TBL] [Abstract][Full Text] [Related]
2. Development of an
Madden PJ; Arif MS; Becker ME; McRaven MD; Carias AM; Lorenzo-Redondo R; Xiao S; Midkiff CC; Blair RV; Potter EL; Martin-Sancho L; Dodson A; Martinelli E; Todd JM; Villinger FJ; Chanda SK; Aye PP; Roy CJ; Roederer M; Lewis MG; Veazey RS; Hope TJ
Front Immunol; 2021; 12():810047. PubMed ID: 35003140
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
4. Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques.
Nomura T; Yamamoto H; Nishizawa M; Hau TTT; Harada S; Ishii H; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Iida S; Katano H; Suzuki T; Park ES; Maeda K; Suzaki Y; Ami Y; Matano T
PLoS Pathog; 2021 Jul; 17(7):e1009668. PubMed ID: 34280241
[TBL] [Abstract][Full Text] [Related]
5. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
Rogers TF; Zhao F; Huang D; Beutler N; Burns A; He WT; Limbo O; Smith C; Song G; Woehl J; Yang L; Abbott RK; Callaghan S; Garcia E; Hurtado J; Parren M; Peng L; Ramirez S; Ricketts J; Ricciardi MJ; Rawlings SA; Wu NC; Yuan M; Smith DM; Nemazee D; Teijaro JR; Voss JE; Wilson IA; Andrabi R; Briney B; Landais E; Sok D; Jardine JG; Burton DR
Science; 2020 Aug; 369(6506):956-963. PubMed ID: 32540903
[TBL] [Abstract][Full Text] [Related]
6. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation.
Van Rompay KKA; Olstad KJ; Sammak RL; Dutra J; Watanabe JK; Usachenko JL; Immareddy R; Roh JW; Verma A; Shaan Lakshmanappa Y; Schmidt BA; Di Germanio C; Rizvi N; Liu H; Ma ZM; Stone M; Simmons G; Dumont LJ; Allen AM; Lockwood S; Pollard RE; Ramiro de Assis R; Yee JL; Nham PB; Ardeshir A; Deere JD; Jain A; Felgner PL; Coffey LL; Iyer SS; Hartigan-O'Connor DJ; Busch MP; Reader JR
PLoS Pathog; 2022 Apr; 18(4):e1009925. PubMed ID: 35443018
[TBL] [Abstract][Full Text] [Related]
7. A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds.
Schöler L; Le-Trilling VTK; Eilbrecht M; Mennerich D; Anastasiou OE; Krawczyk A; Herrmann A; Dittmer U; Trilling M
Front Immunol; 2020; 11():573526. PubMed ID: 33162987
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques.
Ishigaki H; Nakayama M; Kitagawa Y; Nguyen CT; Hayashi K; Shiohara M; Gotoh B; Itoh Y
Virology; 2021 Feb; 554():97-105. PubMed ID: 33412411
[TBL] [Abstract][Full Text] [Related]
9. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
10. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies.
Zhou D; Chan JF; Zhou B; Zhou R; Li S; Shan S; Liu L; Zhang AJ; Chen SJ; Chan CC; Xu H; Poon VK; Yuan S; Li C; Chik KK; Chan CC; Cao J; Chan CY; Kwan KY; Du Z; Lau TT; Zhang Q; Zhou J; To KK; Zhang L; Ho DD; Yuen KY; Chen Z
Cell Host Microbe; 2021 Apr; 29(4):551-563.e5. PubMed ID: 33657424
[TBL] [Abstract][Full Text] [Related]
11. The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues.
Böszörményi KP; Stammes MA; Fagrouch ZC; Kiemenyi-Kayere G; Niphuis H; Mortier D; van Driel N; Nieuwenhuis I; Vervenne RAW; Haaksma T; Ouwerling B; Adema D; Acar RF; Zuiderwijk-Sick E; Meijer L; Mooij P; Remarque EJ; Oostermeijer H; Koopman G; Hoste ACR; Sastre P; Haagmans BL; Bontrop RE; Langermans JAM; Bogers WM; Kondova I; Verschoor EJ; Verstrepen BE
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452537
[TBL] [Abstract][Full Text] [Related]
12. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model.
Haagmans BL; Noack D; Okba NMA; Li W; Wang C; Bestebroer T; de Vries R; Herfst S; de Meulder D; Verveer E; van Run P; Lamers MM; Rijnders B; Rokx C; van Kuppeveld F; Grosveld F; Drabek D; Geurts van Kessel C; Koopmans M; Bosch BJ; Kuiken T; Rockx B
J Infect Dis; 2021 Jun; 223(12):2020-2028. PubMed ID: 34043806
[TBL] [Abstract][Full Text] [Related]
14. MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants.
Lee S; Jang S; Kang J; Park SB; Han YW; Nam H; Kim M; Lee J; Cho KJ; Kim J; Oh M; Ryu J; Seok JH; Kim Y; Lee JB; Park MS; Kim YS; Park H; Kim DS
Front Immunol; 2021; 12():778829. PubMed ID: 34868052
[TBL] [Abstract][Full Text] [Related]
15. Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.
Li D; Luan N; Li J; Zhao H; Zhang Y; Long R; Jiang G; Fan S; Xu X; Cao H; Wang Y; Liao Y; Wang L; Liu L; Liu C; Li Q
Emerg Microbes Infect; 2021 Dec; 10(1):2194-2198. PubMed ID: 34736354
[TBL] [Abstract][Full Text] [Related]
16. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.
Winkler ES; Gilchuk P; Yu J; Bailey AL; Chen RE; Chong Z; Zost SJ; Jang H; Huang Y; Allen JD; Case JB; Sutton RE; Carnahan RH; Darling TL; Boon ACM; Mack M; Head RD; Ross TM; Crowe JE; Diamond MS
Cell; 2021 Apr; 184(7):1804-1820.e16. PubMed ID: 33691139
[TBL] [Abstract][Full Text] [Related]
17. Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.
Zhao S; Zhang H; Yang X; Zhang H; Chen Y; Zhan Y; Zhang X; Jiang R; Liu M; Liu L; Chen L; Tang W; Peng C; Gao X; Zhang Z; Shi Z; Gong R
Nat Commun; 2021 Aug; 12(1):4887. PubMed ID: 34373446
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibody: a savior in the Covid-19 disease.
Gupta SL; Jaiswal RK
Mol Biol Rep; 2022 Mar; 49(3):2465-2474. PubMed ID: 34988889
[TBL] [Abstract][Full Text] [Related]
19. The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines.
Murano K; Guo Y; Siomi H
Biochem Soc Trans; 2021 Dec; 49(6):2879-2890. PubMed ID: 34854887
[TBL] [Abstract][Full Text] [Related]
20. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation.
Van Rompay KKA; Olstad KJ; Sammak RL; Dutra J; Watanabe JK; Usachenko JL; Immareddy R; Roh JW; Verma A; Shaan Lakshmanappa Y; Schmidt BA; Di Germanio C; Rizvi N; Stone M; Simmons G; Dumont LJ; Allen AM; Lockwood S; Pollard RE; de Assis RR; Yee JL; Nham PB; Ardeshir A; Deere JD; Patterson J; Jain A; Felgner PL; Iyer SS; Hartigan-O'Connor DJ; Busch MP; Reader JR
bioRxiv; 2021 Sep; ():. PubMed ID: 34494025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
